CD79A and infection: These results suggest that our vaccine candidate can induce the secretion of anti-hMPV and anti-P antibodies at early (7 dpi) and late (28 dpi) timepoints of infection with hMPV, yielding an early secretion of IgA and the late secretion of IgG.